Inclusion Criteria:

          -  Morphologic confirmation of a diagnosis of AML or ALL at MSKCC

          -  Patients will have completed induction therapy, achieved 1st CR and will have
             completed any planned postremission therapy. Patients are not candidates for
             allogeneic stem cell transplantation. For purposes of this study, patients who are not
             candidates for allogeneic stem cell transplantation shall be defined as 1) those who
             do not meet the eligibility criteria of an open allogeneic transplant protocol or 2)
             those who do not have a suitable available HLA matched donor available or 3) those who
             refuse to undergo stem cell transplantation or 4) those patients whose disease is
             characterized by "good risk" features (For AML the following cytogenetic subtypes:
             t(8;21), inv (16), or t(16;16), t(15;17), normal karyotype with mutated NPM1 and
             negative for tandem duplication of FLT-3. For ALL: T cell phenotype of any B lineage
             disease exclusive of t(9;22) or t(4;11) in whom allogenic stem cell transplantation in
             1st CR would not be offered as standard of care.

          -  Alternatively, those patients greater than or equal to 60 years of age who have
             achieved 1st CR and in whom no further postremission chemotherapy is planned may be
             enrolled

          -  Patients must have documented WT1 + disease. For purpose of this study, this is
             defined as detectable presence of any WT1 transcript via RT-PCR on a bone marrow
             performed at MSKCC within 4 weeks prior to the administration of the first dose of
             vaccine.

          -  Patients must be within 2 years of achieving CR following chemotherapy

          -  At least 4 weeks must have elapsed between the patient's last chemotherapy or
             radiation treatment and the first vaccination.

          -  Age ≥ 18 years

          -  Karnofsky performance status ≥ 50%

          -  Hematologic parameters:

        Absolute neutrophil count (ANC) ≥ 1000/μl

          -  Platelets > 50k/ μl

        Biochemical parameters:

          -  Total bilirubin ≤ 2.0 mg/dl AST and ALT ≤ 2.5 x upper limits of normal

          -  Creatinine ≤ 2.0 mg/dl

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with documented evidence of leptomeningeal disease

          -  Patients who have undergone autologous or allogeneic stem cell transplantation

          -  Patients with active infection requiring systemic antimicrobials

          -  Patients taking systemic corticosteroids

          -  Patients with serious unstable medical illness